A Pilot Clinical Study to Evaluate the Feasibility of Using the SPC Test
NCT ID: NCT06521528
Last Updated: 2024-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
237 participants
OBSERVATIONAL
2019-09-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Patient Classifier (SPC) Prediction for Stage II and III Advanced Gastric Cancer
NCT04600518
Prospective Assessment of nProfiler® 1 on Prognosis and Chemotherapy Response for Gastric Cancer
NCT04487717
A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy
NCT03086291
PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer
NCT01152853
A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery (CLASSIC)
NCT03403296
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Feasibility cohort
patients who underwent gastrectomy between September 2019 and August 2020 across nine hospitals.
nProfiler I Stomach Cancer Assay Kit
nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nProfiler I Stomach Cancer Assay Kit
nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* having a histologically confirmed diagnosis of stage II or III AGC according to the American Joint Committee on Cancer (AJCC) staging system (sixth edition)
* underwent radical gastrectomy without prior neo-adjuvant chemoradiotherapy and did not receive adjuvant chemotherapy
* having no visually or microscopically detectable residual tumors.
Exclusion Criteria
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novomics. Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young-Woo Kim, MD., Ph.D
Role: PRINCIPAL_INVESTIGATOR
National Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novomics. Co., Ltd.
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Feasibility Study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.